Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, forced-dose titration, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention deficit/hyperactivity disorder (ADHD)

Next Previous
X
Search
Trial Profile

A phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, forced-dose titration, safety and efficacy study of lisdexamfetamine dimesylate (LDX) in adolescents aged 13-17 with attention deficit/hyperactivity disorder (ADHD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lisdexamfetamine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Registrational; Therapeutic Use
  • Sponsors Shire

    • Most Recent Events

    • 02 Feb 2011 Health Canada approved lisdexamfetamine dimesylate capsules for the treatment of ADHD in adolescents and adults based on data from this trial and trial profile 700013304, according to a Shire media release.
    • 15 Nov 2010 Vyvanse approved by the FDA for the treatment of ADHD in adolescents aged 13-17 years, based on the resutls of this study, according to a Shire media release.
    • 22 May 2010 Primary endpoint 'Attention Deficit Hyperactivity Disorder Rating Scale' has been met.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top